Pioneering Regenerative Medicine
Without Immunosuppression
We are a data-driven and patient-centric preclinical regenerative medicine company developing potentially first-in-class technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technology platform, we are advancing a pipeline of product candidates that have the potential to cure various diseases. These platforms include iTOL-200, iTOL-201 and iTOL-401.
Pioneering Regenerative Medicine
Without Immunosuppression
We are a data-driven and patient-centric preclinical regenerative medicine company developing potentially first-in-class technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technology platform, we are advancing a pipeline of product candidates that have the potential to cure various diseases. These platforms include iTOL-200, iTOL-201 and iTOL-401.
iTOL-100:
Immunomodulatory Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL biotin-PEG microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce durable immune tolerance without the need for life-long immunosuppression.
iTOL-100:
Immunomodulatory Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL biotin-PEG microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce durable immune tolerance without the need for life-long immunosuppression.
iTOL-101 and iTOL-102: Developing a Potential Cure for Type 1 Diabetes
iTOL-101 utilizes allogeneic cadaveric pancreatic islets in combination with iTOL-100 and is being developed as a potential cure for Type 1 Diabetes. In a pre-clinical non-human primate study, Insulin-Dependent Diabetes, pancreatic islets derived from cadavers co-implanted with iTOL-100 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. Our iTOL-102 program leverages significant advancements in stem cells to derive human pancreatic islets which allows an inexhaustible supply of insulin-producing cells and is being developed as a potential cure for Type 1 Diabetes.
Development Pipeline
1: Development of iTOL-401 is subject to the entry of a license agreement with Georgia Tech Research Corporation
We Were 1 of 3 Companies Selected to Participate in the Disruptive Healthcare
Technology Showcase at the US Capitol on June 12, 2023.
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment
This submission comes after successful INTERACT meeting with the FDA earlier this year.NLS Pharmaceutics and Kadimastem working to close merger by the end of January 2025ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL, December 19, 2024. NLS Pharmaceutics Ltd. (Nasdaq:...
The BIRD Foundation has Approved an Additional Payment to Kadimastem and Miami Based iTolerance Inc. from the Total Grant for the Continued Co-Development of the Innovative Treatment for Diabetes The Additional Payment is for the Progress Presented by the Companies in the Development of the Treatment
Ness Ziona, Israel, November 27th, 2024 , Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, developing and manufacturing "off-the-shelf" allogeneic cell products using its innovative groundbreaking platform technology to develop treatments for...
The Diabetes Research Institute, University of Miami, Announces Breakthrough Transplantation Approach for the Treatment of Type 1 Diabetes at ADA 2024
Novel Combination of Tolerance-Inducing Agent and Human Stem Cell-Derived Islets Demonstrates Functional Insulin Release and Disease Reversal in a Model of DiabetesMIAMI, FL / June 24, 2024 / iTolerance Inc. announced today that the Diabetes Research Institute (DRI)...